{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:19:41Z","timestamp":1775081981910,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,7]],"date-time":"2015-11-07T00:00:00Z","timestamp":1446854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF J3353"],"award-info":[{"award-number":["FWF J3353"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00277-015-2541-6","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T19:22:32Z","timestamp":1446837752000},"page":"211-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia"],"prefix":"10.1007","volume":"95","author":[{"given":"F.","family":"Efficace","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Breccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Russo Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Luciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Galimberti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Turri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tiribelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mandelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,7]]},"reference":[{"key":"2541_CR1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2012.01.001","volume":"84","author":"M Breccia","year":"2012","unstructured":"Breccia M, Tiribelli M, Alimena G (2012) Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data. Crit Rev Oncol Hematol 84:93\u2013100","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"2541_CR2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00277-014-2041-0","volume":"93","author":"U Proetel","year":"2014","unstructured":"Proetel U, Pletsch N, Lauseker M et al (2014) Older patients with chronic myeloid leukemia (\u226565\u00a0years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol 93(7):1167\u201376","journal-title":"Ann Hematol"},{"key":"2541_CR3","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J et al (2015) The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia 29:1336\u201343","journal-title":"Leukemia"},{"key":"2541_CR4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","volume":"23","author":"M Rohrbacher","year":"2009","unstructured":"Rohrbacher M, Berger U, Hochhaus A et al (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 23:602\u20134","journal-title":"Leukemia"},{"key":"2541_CR5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/003693300404900305","volume":"49","author":"SJ Harrison","year":"2004","unstructured":"Harrison SJ, Johnson PR, Holyoake TL (2004) The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000. Scott Med J 49:87\u201390","journal-title":"Scott Med J"},{"key":"2541_CR6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1586\/17474086.2013.837279","volume":"6","author":"G Gugliotta","year":"2013","unstructured":"Gugliotta G, Castagnetti F, Fogli M et al (2013) Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. Expert Rev Hematol 6:563\u201374","journal-title":"Expert Rev Hematol"},{"key":"2541_CR7","first-page":"41","volume":"29","author":"AW Smith","year":"2008","unstructured":"Smith AW, Reeve BB, Bellizzi KM et al (2008) Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev 29:41\u201356","journal-title":"Health Care Financ Rev"},{"key":"2541_CR8","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0021-9681(70)90054-8","volume":"23","author":"AR Feinstein","year":"1970","unstructured":"Feinstein AR (1970) The pre-therapeutic classification of co-morbidity in chronic disease. J Cron Dis 23:455\u2013468","journal-title":"J Cron Dis"},{"key":"2541_CR9","first-page":"168","volume":"1","author":"T Hughes","year":"2013","unstructured":"Hughes T, White D (2013) Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. ASH Educ Book 1:168\u2013175","journal-title":"ASH Educ Book"},{"key":"2541_CR10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994\u20131004","journal-title":"N Engl J Med"},{"key":"2541_CR11","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S et al (2011) Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 29:2514\u201320","journal-title":"J Clin Oncol"},{"key":"2541_CR12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/cncr.11629","volume":"98","author":"J Cortes","year":"2003","unstructured":"Cortes J, Talpaz M, O\u2019Brien S et al (2003) Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 98:1105\u201313","journal-title":"Cancer"},{"key":"2541_CR13","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F et al (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117:5591\u20139","journal-title":"Blood"},{"key":"2541_CR14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","volume":"117","author":"J Pinilla-Ibarz","year":"2011","unstructured":"Pinilla-Ibarz J, Cortes J, Mauro MJ (2011) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications. Cancer 117:688\u201397","journal-title":"Cancer"},{"key":"2541_CR15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/asheducation-2011.1.128","volume":"2011","author":"A Hochhaus","year":"2011","unstructured":"Hochhaus A (2011) Educational session: managing chronic myeloid leukemia as a chronic disease. Hematol Am Soc Hematol Educ Program 2011:128\u201335","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2541_CR16","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554\u201360","journal-title":"Blood"},{"key":"2541_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware Jr","year":"1992","unstructured":"Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u201383","journal-title":"Med Care"},{"issue":"S2","key":"2541_CR18","first-page":"189","volume":"95","author":"F Efficace","year":"2010","unstructured":"Efficace F, Breccia M, Baccarani M et al (2010) Development and feasibility of a patient-reported symptom checklist for chronic myeloid leukemia patients [abstract]. Haematologica 95(S2):189, Abstract 0465","journal-title":"Haematologica"},{"key":"2541_CR19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365\u2013376","journal-title":"J Natl Cancer Inst"},{"key":"2541_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL et al (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373\u201383","journal-title":"J Chronic Dis"},{"key":"2541_CR21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pon.635","volume":"12","author":"PA Parker","year":"2003","unstructured":"Parker PA, Baile WF, de Moor C et al (2003) Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology 12:183\u201393","journal-title":"Psychooncology"},{"key":"2541_CR22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jgo.2014.08.001","volume":"5","author":"Y Rottenberg","year":"2014","unstructured":"Rottenberg Y, Litwin H, Manor O et al (2014) Prediagnostic self-assessed health and extent of social networks predict survival in older individuals with cancer: a population based cohort study. J Geriatr Oncol 5:400\u20137","journal-title":"J Geriatr Oncol"},{"key":"2541_CR23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1207\/s15327752jpa5503&4_17","volume":"55","author":"GD Zimet","year":"1990","unstructured":"Zimet GD, Powell SS, Farley GK et al (1990) Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess 55:610\u20137","journal-title":"J Pers Assess"},{"key":"2541_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/009286150303700105","volume":"37","author":"J Sloan","year":"2003","unstructured":"Sloan J, Symonds T, Vargas-Chanes D, Fridley B (2003) Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials. Drug Inf J 37:23\u201331","journal-title":"Drug Inf J"},{"key":"2541_CR25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Saussele","year":"2015","unstructured":"Saussele S, Krauss MP, Hehlmann R et al (2015) Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126:42\u20139","journal-title":"Blood"},{"key":"2541_CR26","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1007\/s11764-013-0299-1","volume":"7","author":"PA Vissers","year":"2013","unstructured":"Vissers PA, Thong MS, Pouwer F et al (2013) The impact of comorbidity on health-related quality of life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv 7:602\u201313","journal-title":"J Cancer Surviv"},{"key":"2541_CR27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1200\/JCO.2011.40.6249","volume":"31","author":"SK Smith","year":"2013","unstructured":"Smith SK, Mayer DK, Zimmerman S et al (2013) Quality of life among long-term survivors of non-Hodgkin lymphoma: a follow-up study. J Clin Oncol 31:272\u20139","journal-title":"J Clin Oncol"},{"key":"2541_CR28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/bjh.12698","volume":"164","author":"A Korszun","year":"2014","unstructured":"Korszun A, Sarker SJ, Chowdhury K et al (2014) Psychosocial factors associated with impact of cancer in longterm haematological cancer survivors. Br J Haematol 164:790\u2013803","journal-title":"Br J Haematol"},{"key":"2541_CR29","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M et al (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27:1511\u20139","journal-title":"Leukemia"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2541-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2541-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2541-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T05:50:36Z","timestamp":1567317036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2541-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,7]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2541"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2541-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,7]]}}}